Nasdaq · Biotech stocks database
IAM — Iambic Therapeutics Inc.
IAM (Iambic Therapeutics Inc.) stock: $12.95, $613.9M market cap. Next expected readout: Dec-27. Lead program: IAM1363 (HER2 Mutation-Related Tumors), Phase 1. Data from Fully Diluted's biotech stocks database.
Enterprise value
Not disclosed
Balance sheet
| Cash | Not disclosed |
|---|
| Debt | Not disclosed |
|---|
| Net cash | Not disclosed |
|---|
| Enterprise value | Not disclosed |
|---|
| Basic shares | Not disclosed |
|---|
| Fully diluted shares | Not disclosed |
|---|
| Fully diluted market cap | Not disclosed |
|---|
| Cash per share | Not disclosed |
|---|
Share structure
Cap table components pending verification.
Price history
Loading IAM daily closes…
Loading price history…
Asset data not yet available for this company.
Pipeline
| Lead drug | IAM1363 |
|---|
| Lead indication | HER2 Mutation-Related Tumors |
|---|
| Lead phase | Phase 1 |
|---|
| Active trials | 1 |
|---|
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.